The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells

Combination treatment is a promising strategy to improve prognosis of hepatocellular carcinoma (HCC). Sorafenib is a traditional first-line agent approved for the treatment of advanced HCC, though with limited efficacy. Previously, we reported that lonafarnib, an orally bioavailable non-peptide inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jialiang, Wei, Huan, Huang, Yanlin, Chen, Dongmei, Zeng, Guofen, Lian, Yifan, Huang, Yuehua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710066/
https://www.ncbi.nlm.nih.gov/pubmed/31409760
http://dx.doi.org/10.18632/aging.102165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710066/
https://www.ncbi.nlm.nih.gov/pubmed/31409760
http://dx.doi.org/10.18632/aging.102165

Ejemplares similares